Abstract:Acute myeloid leukemia (AML) is the most common type of acute leukemia in adults. It is estimated that 13,410 cases will be diagnosed and 8,990 will die of AML in the United States in 2007 (http://seer.cancer.gov). AML is a genetically diverse hematopoietic malignancy with variable response to treatment. Expression profiling of protein-coding genes using DNA microarray in AML has resulted in inconsistent data from different laboratories. Therefore, further validation of these observations in large cohorts and in independent studies is definitely required before clinical application becomes feasible. Recently, Golub and colleagues described a new, bead-based flow cytometric microRNA (miRNAs, miRs) expression profiling method that could successfully classify tumors. MiRNAs are endogenous ∼22 nucleotide non-coding RNAs, which can function as oncogenes and tumor suppressors. To provide new insights into the complex genetic alterations in leukemogenesis and to identify novel markers for diagnosis and treatment of AML, we performed a genome-wide analysis of miRNA expression profiles using the bead-based method on 54 AML samples with common translocations including t(15;17), t(8;21), inv(16), and 11q23 rearrangement, along with normal controls. In both unsupervised and supervised hierarchical cluster analyses, we observed that t(15;17) samples grouped together as one cluster, as do the 11q23 rearrangement samples. Interestingly, t(8;21) and inv(16), both CBF (core-binding factor) AMLs, grouped together as a unique cluster. Forty-one miRNAs exhibited significantly differential expression between different subtypes of AMLs, and/or between AMLs and normal controls. Notably, expression signature of a minimal number of two, three, and seven miRNAs could be used for class prediction of CBF, t(15;17), and 11q23 rearrangement AMLs, respectively, with an overall diagnostic accuracy of 94–96%. We further showed that overexpression of the two discriminatory miRNAs in CBF AML is associated with epigenetic regulation, rather than DNA copy number amplification. Moreover, several important target genes of these discriminatory miRNAs have also been validated. We are currently exploring the role of these discriminatory miRNAs and their critical target genes in the development of AML using in vitro and in vivo models. This work will enhance our understanding of the biological role of these miRNAs and their targets in leukemogenesis.

LncRNA H19 Regulates ID2 Expression Through Competitive Binding to Hsa-Mir-19a/b in Acute Myelocytic Leukemia.

Mir-22 Has a Potent Anti-Tumour Role with Therapeutic Potential in Acute Myeloid Leukaemia

Identification of TET1⊣miR-22⊣CREB-MYC Signaling Reveals Potent Tumor-Suppressor Role of Mir-22 in Acute Myeloid Leukemia

Distinct Microrna Expression Profiles In Acute Myeloid Leukemia With Common Translocations

Mir-196B Directly Targets Both HOXA9/MEIS1 Oncogenes and FAS Tumour Suppressor in MLL-rearranged Leukaemia.

MicroRNA Expression Profiles in Acute Myeloid Leukemia with Common Translocations.

Long Non-Coding RNA HOTAIR Regulates Myeloid Differentiation Through the Upregulation of P21 Via Mir-17-5p in Acute Myeloid Leukaemia

Long Non-Coding RNA LINC01018 Inhibits the Progression of Acute Myeloid Leukemia by Targeting Mir-499A-5p to Regulate PDCD4.

H22954, a novel long non-coding RNA down-regulated in AML, inhibits cancer growth in a BCL-2-dependent mechanism.

The Non-Cell-autonomous Function of ID1 Promotes AML Progression Via ANGPTL7 from the Microenvironment.

MiRNA-142-3P and FUS can be Sponged by Long Noncoding RNA DUBR to Promote Cell Proliferation in Acute Myeloid Leukemia

The Knockdown of MAGI2-AS3 Inhibits Drug Resistance in Acute Myeloid Leukemia by Up Regulating Mir-155

LncRNA ID2-AS1 Suppresses Tumor Metastasis by Activating the HDAC8/ID2 Pathway in Hepatocellular Carcinoma.

[Research Progress on Role of Long Non-Coding RNA in Occurrence and Development of Acute Myeloid Leukemia--Review]

Investigating the Microrna-Mrna Regulatory Network in Acute Myeloid Leukemia

Long non-coding RNA H19: a potential biomarker and therapeutic target in human malignant tumors

Upregulation of Lncrna CCAT2 Predicts Poor Prognosis in Patients with Acute Myeloid Leukemia and is Correlated with Leukemic Cell Proliferation.

Transcriptome Analysis Identifies Key Regulators and Networks in Acute Myeloid Leukemia.

LncRNA MAGI2-AS3 inhibits the self-renewal of leukaemic stem cells by promoting TET2-dependent DNA demethylation of the LRIG1 promoter in acute myeloid leukaemia

LncRNA HOTAIRM1 is Involved in the Progression of Acute Myeloid Leukemia Through Targeting Mir-148B.

Overexpression of long noncoding RNA HOXA‐AS2 predicts an adverse prognosis and promotes tumorigenesis via SOX4/PI3K/AKT pathway in acute myeloid leukemia